Surface-tethered ROS-responsive micelle backpacks for boosting mesenchymal stem cell vitality and modulating inflammation in ischemic stroke treatment

You, Yang; Liu, Yipu; Ma, Chuchu; Xu, Jianpei; Xie, Laozhi; Tong, Shiqiang; Sun, Yinzhe; Ma, Fenfen; Huang, Yukun; Liu, Junbin; Xiao, Wenze; Dai, Chengxiang; Li, Suke; Lei, Jigang; Mei, Qiyong; Gao, Xiaoling; Chen, Jun

doi:10.1016/j.jconrel.2023.08.039

Cited by 10 publications

(5 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specific pathophysiological changes occur in the IS microenvironment, and multiple mechanisms can induce ROS production or worsen oxidative stress injury. You et al, 2023 SCHEME 1 Endogenous and exogenous stimuli-responsive nanomedicines for the treatment of ischemic stroke.…”

Section: Endogenous Stimuli-responsive Nanomedicines 21 Ros Stimuli-r...mentioning

confidence: 99%

“…Notably, MSAOR@Cur exhibited a remarkable enhancement in post-stroke neurological function scores, thus offering a novel strategy for the neuroprotective treatment of stroke. You et al, 2023 developed ROS-responsive micelles loaded with luteolin and conducted in vivo experiments using the MCAO rat model. Under the high-level of ROS generated in the ischemic microenvironment, Immunofluorescence staining was performed on BV2 cells at the periphery of the injury site.…”

Section: Endogenous Stimuli-responsive Nanomedicines 21 Ros Stimuli-r...mentioning

confidence: 99%

See 1 more Smart Citation

Application of stimuli-responsive nanomedicines for the treatment of ischemic stroke

Zhan,

Dai,

Ding

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Ischemic stroke (IS) refers to local brain tissue necrosis which is caused by impaired blood supply to the carotid artery or vertebrobasilar artery system. As the second leading cause of death in the world, IS has a high incidence and brings a heavy economic burden to all countries and regions because of its high disability rate. In order to effectively treat IS, a large number of drugs have been designed and developed. However, most drugs with good therapeutic effects confirmed in preclinical experiments have not been successfully applied to clinical treatment due to the low accumulation efficiency of drugs in IS areas after systematic administration. As an emerging strategy for the treatment of IS, stimuli-responsive nanomedicines have made great progress by precisely delivering drugs to the local site of IS. By response to the specific signals, stimuli-responsive nanomedicines change their particle size, shape, surface charge or structural integrity, which enables the enhanced drug delivery and controlled drug release within the IS tissue. This breakthrough approach not only enhances therapeutic efficiency but also mitigates the side effects commonly associated with thrombolytic and neuroprotective drugs. This review aims to comprehensively summarize the recent progress of stimuli-responsive nanomedicines for the treatment of IS. Furthermore, prospect is provided to look forward for the better development of this field.

show abstract

Section: Endogenous Stimuli-responsive Nanomedicines 21 Ros Stimuli-r...mentioning

confidence: 99%

Section: Endogenous Stimuli-responsive Nanomedicines 21 Ros Stimuli-r...mentioning

confidence: 99%

Application of stimuli-responsive nanomedicines for the treatment of ischemic stroke

Zhan,

Dai,

Ding

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…2 Endogenous stimuli-responsive nanomedicines 2.1 ROS stimuli-responsive nanomedicines Specific pathophysiological changes occur in the IS microenvironment, and multiple mechanisms can induce ROS production or worsen oxidative stress injury. You et al, 2023 SCHEME 1 Endogenous and exogenous stimuli-responsive nanomedicines for the treatment of ischemic stroke.…”

Section: Nanomedicine Therapymentioning

confidence: 99%

“…Notably, MSAOR@Cur exhibited a remarkable enhancement in post-stroke neurological function scores, thus offering a novel strategy for the neuroprotective treatment of stroke. You et al, 2023 developed ROS-responsive micelles loaded with luteolin and conducted in vivo experiments using the MCAO rat model. Under the high-level of ROS generated in the ischemic microenvironment, Immunofluorescence staining on BV2 cells at the periphery of the injury site.…”

Section: Nanomedicine Therapymentioning

confidence: 99%

Bioactive Materials for Disease Diagnosis and Therapy

2024

Frontiers Research Topics

View full text Add to dashboard Cite

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals. Frontiers journal seriesThe Frontiers journal series is a multi-tier and interdisciplinary set of openaccess, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the Frontiers journal series operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too. Dedication to qualityEach Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public -and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation. What are Frontiers Research Topics?Frontiers Research Topics are very popular trademarks of the Frontiers journals series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

show abstract

“…Oxidative stress is a condition characterized by an imbalance between reactive oxygen species (ROS) production and antioxidant defense systems ( You et al, 2023 ). During reperfusion following an ischemic stroke, the reintroduction of blood flow causes a paradoxical surge in ROS production, exacerbating the injury ( Wu et al, 2021 ; Hong et al, 2023 ).…”

Section: Oxidative Stressmentioning

confidence: 99%

Emerging diagnostic markers and therapeutic targets in post-stroke hemorrhagic transformation and brain edema

Yao,

Liu,

et al. 2023

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Stroke is a devastating condition that can lead to significant morbidity and mortality. The aftermath of a stroke, particularly hemorrhagic transformation (HT) and brain edema, can significantly impact the prognosis of patients. Early detection and effective management of these complications are crucial for improving outcomes in stroke patients. This review highlights the emerging diagnostic markers and therapeutic targets including claudin, occludin, zonula occluden, s100β, albumin, MMP-9, MMP-2, MMP-12, IL-1β, TNF-α, IL-6, IFN-γ, TGF-β, IL-10, IL-4, IL-13, MCP-1/CCL2, CXCL2, CXCL8, CXCL12, CCL5, CX3CL1, ICAM-1, VCAM-1, P-selectin, E-selectin, PECAM-1/CD31, JAMs, HMGB1, vWF, VEGF, ROS, NAC, and AQP4. The clinical significance and implications of these biomarkers were also discussed.

show abstract

Surface-tethered ROS-responsive micelle backpacks for boosting mesenchymal stem cell vitality and modulating inflammation in ischemic stroke treatment

Cited by 10 publications

References 62 publications

Application of stimuli-responsive nanomedicines for the treatment of ischemic stroke

Application of stimuli-responsive nanomedicines for the treatment of ischemic stroke

Bioactive Materials for Disease Diagnosis and Therapy

Emerging diagnostic markers and therapeutic targets in post-stroke hemorrhagic transformation and brain edema

Contact Info

Product

Resources

About